Theriva Biologics, Inc. (TOVX)

Theriva Biologics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-18.35	-20.03	-23.19	-12.56	-16.08
Depreciation & Amortization	0.52	0.27	0.09	0.2	0.24
Share-Based Compensation	0.55	0.48	0.42	0.35	0.34
Other Operating Activities	-1.72	-0.14	0.87	-2.68	0.85
Operating Cash Flow	-19	-19.08	-12.89	-12.17	-13.87
Capital Expenditures	-0.2	-0.12	-0.01	-0.01	0
Acquisitions	0	-4.28	0	0	0
Investing Cash Flow	-0.2	-4.4	-0.01	-0.01	0
Share Issuance / Repurchase	2.22	-0.29	74	3.36	0
Debt Issued / Paid	-0.08	-1.38	0	0	0
Other Financing Activities	-1.52	-0.27	-	-	-
Financing Cash Flow	0.63	-1.93	74	3.36	0
Exchange Rate Effect	-0.03	-0.03	0	0	0
Net Cash Flow	-18.61	-25.41	61.1	-8.82	-13.87
Free Cash Flow	-19.2	-19.2	-12.9	-12.18	-13.87
Free Cash Flow Per Share	-1.19	-1.25	-1.06	-6.41	-8.44

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).